Mekinist (trametinib) / Novartis, Japan Tobacco, BeiGene 
Welcome,         Profile    Billing    Logout  

90 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mekinist (trametinib) / Novartis, BeiGene
NCT03975829 / 2018-004459-19: Pediatric Long-Term Follow-up and Rollover Study

Recruiting
4
250
Europe, Canada, Japan, US, RoW
dabrafenib, DRB436, trametinib, TMT212
Novartis Pharmaceuticals, Novartis Pharma AG
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
05/26
05/26
NCT03340506 / 2017-001987-39: Dabrafenib and/or Trametinib Rollover Study

Recruiting
4
100
Europe, Japan, US, RoW
dabrafenib, trametinib
Novartis Pharmaceuticals
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
12/27
12/27
COMBI-AD, NCT01682083 / 2012-001266-15: Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma ().

Checkmark Data from COMBI-AD trial in combination with Mekinist for melanoma at ASCO 2020
May 2020 - May 2020: Data from COMBI-AD trial in combination with Mekinist for melanoma at ASCO 2020
Checkmark Data from COMBI-AD trial in combination with Tafinlar for melanoma at ASCO 2020
May 2020 - May 2020: Data from COMBI-AD trial in combination with Tafinlar for melanoma at ASCO 2020
Checkmark From COMBI-AD trial in combination with Mekinist at ASCO 2020
More
Completed
3
870
Europe, Canada, Japan, US, RoW
Dabrafenib, GSK2118436, Trametinib, GSK1120212, Placebos
Novartis Pharmaceuticals
Melanoma
06/17
07/23
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS

Not yet recruiting
3
960
Europe
CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE
INSERM, Institut National du Cancer (INCa)
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
COMBI-i, NCT02967692 / 2016-002794-35: A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Checkmark From COMBI-i trial in combination with Tafinlar and Mekinist for BRAFV600 metastatic melanoma at ESMO 2020
Sep 2020 - Sep 2020: From COMBI-i trial in combination with Tafinlar and Mekinist for BRAFV600 metastatic melanoma at ESMO 2020
Checkmark From COMBI-i trial in combination with Tafinlar and spartalizumab for BRAFV600 metastatic melanoma
Sep 2020 - Sep 2020: From COMBI-i trial in combination with Tafinlar and spartalizumab for BRAFV600 metastatic melanoma
Checkmark From COMBI-i trial in combination with spartalizumab and Mekinist for BRAFV600 metastatic melanoma
More
Active, not recruiting
3
569
Europe, Canada, Japan, US, RoW
Spartalizumab, PDR001, Placebo, Dabrafenib, Trametinib
Novartis Pharmaceuticals
Melanoma
08/20
08/24
NCT04940052: Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer

Calendar Jan 2024 - Dec 2024: Data from trial in combination with Tafinlar for differentiated thyroid cancer
Active, not recruiting
3
153
Canada, US, RoW
Dabrafenib, Trametinib, Trametinib placebo, Dabrafenib placebo
Novartis Pharmaceuticals
Differentiated Thyroid Cancer
05/27
06/27
SEACRAFT-2, NCT06346067: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma

Recruiting
3
470
US
Naporafenib, ERAS-254, LXH254, Dacarbazine, DTIC, Temozolomide, Temodar, TMZ, Trametinib, Mekinist
Erasca, Inc.
Advanced or Metastatic NRAS-mutant Melanoma
04/28
12/28
NADINA, NCT04949113 / 2021-001492-16: Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

Active, not recruiting
3
423
Europe, US, RoW
Neoadjuvant ipilimumab + nivolumab, Yervoy + Opdivo, Adjuvant nivolumab, Opdivo
The Netherlands Cancer Institute, Bristol-Myers Squibb
Malignant Melanoma Stage III
01/24
12/28
2013-001627-39: LOGS: A randomized phase II/III study to assess the efficacy of trametinib (GSK 1120212) in patients with recurrent or progressive low-grade serous ovarian cancer of peritoneal cancer (GOG-0281)

Ongoing
2/3
250
Europe
Trametinib, Letrozole, Tamoxifen, Paclitaxel, Pegylated Liposomal Doxorubicin, Topotecan, GSK1120212, Film-coated tablet, Tablet, Concentrate for solution for injection/infusion, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Trametinib, Femara, tamoxifen, Paclitaxel, Caelyx, Hycamptin
NHS Greater Glasgow and Clyde, University of Glasgow, GlaxoSmithKline,
Recurrent low grade serous ovarian or peritoneal cancer, Ovarian or peritoneal cancer which has came back or started to grow again, Diseases [C] - Cancer [C04]
 
 
2019-003573-26: Evaluating the safety and efficacy of Trametinib in Arterio-Venous Malformations that are refractory to standard care

Not yet recruiting
2
20
Europe
Mekinist, Coated tablet, Mekinist
Cliniques universitaires Saint-Luc, Novartis
Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated, Arteriovenous Malformations, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2013-002616-28: A trial with patients who have a tumor that is too big to resect via operation, to treat them with systemic treatment to downsize the tumor, so that after 8 weeks the tumor can be resected and the patient is cured.

Ongoing
2
25
Europe
dabrafenib, trametinib, GSK2118436, GSK1120212, Capsule, Tablet
NKI-AVL, GlaxoSmithKline
unresectable stage III/IV melanoma, skin cancer that has spread out through the body, Diseases [C] - Cancer [C04]
 
 
2016-005228-27: A trial to compare giving chemotherapy intermittently to chemotherapy administered continuously to patients with inoperable or metastatic melanoma.

Not yet recruiting
2
150
Europe
dabrafenib, trametinib, Capsule, hard, Film-coated tablet, dabrafenib, trametinib
Cambridge University Hospitals NHS Foundation Trust, National Institute for Health Research
BRAFV600 mutant stage 3 unresectable or metastatic melanoma, Advanced melanoma (skin cancer) which has an abnormal gene called BRAF., Diseases [C] - Cancer [C04]
 
 
2019-001317-16: The TRAIN study: TRAmetinib In Neurofibromatosis type 1 related symptomatic plexiform neurofibromas De TRAIN studie: TRAmetinib voor Neurofibromatose type 1 gerelateerde pleximorme neurofibromen

Ongoing
2
30
Europe
Film-coated tablet, Mekinist
ErasmusMC, Stichting NF, Novartis
Adult patients (age >17 years) with (mosaic) NF1 with inoperable symptomatic plexiform neurofibromas, Adult patients (age >17 years) with (mosaic) NF1 with inoperable symptomatic plexiform neurofibromas, Diseases [C] - Nervous System Diseases [C10]
 
 
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig

Not yet recruiting
2
30
Europe
Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo
Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark
Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04]
 
 
CDRB436G2201, NCT02684058 / 2015-004015-20: Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Checkmark From trial in combination with Tafinlar in BRAF V600mutant glioma
Jun 2022 - Jun 2022: From trial in combination with Tafinlar in BRAF V600mutant glioma
Completed
2
151
Europe, Canada, Japan, US, RoW
Dabrafenib, DRB436, trametinib, TMT212, Carboplatin, Vincristine
Novartis Pharmaceuticals
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Iponeurocytoma
08/21
04/23
NCT03149029: Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

Active, not recruiting
2
16
US
Pembrolizumab, Keytruda, Dabrafenib, Tafinlar, Trametinib, Mekinist
Massachusetts General Hospital, Merck Sharp & Dohme LLC
Metastatic Melanoma
12/21
12/24
NeoTrio, NCT02858921: Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Active, not recruiting
2
60
RoW
Dabrafenib, Tafinlar, Trametinib, Mekinist, Pembrolizumab, Keytruda
Melanoma Institute Australia, Merck Sharp & Dohme LLC, Novartis
Melanoma
01/22
11/24
2021-006276-16: A phase 2 clinical research study to examine if trametinib and hydroxychloroquine will improve outcomes for patients with advanced pancreatic cancer.

Not yet recruiting
2
22
Europe
Trametinib, Hydroxychloroquine sulfate, Film-coated tablet, Mekinist®, Hydroxychloroquine sulfate
Cancer Trials Ireland, Cancer Trials Ireland
Metastatic refractory pancreatic cancer., Advanced pancreatic cancer., Diseases [C] - Cancer [C04]
 
 
NCT03668431: Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Recruiting
2
25
US
Dabrafenib, Tafinlar®, Trametinib, Mekinist®, PDR001
Massachusetts General Hospital, Novartis, Stand Up To Cancer
Metastatic Colorectal Cancer
09/22
12/22
CAcTUS, NCT03808441: - Circulating Tumour DNA Guided Switch

Active, not recruiting
2
21
Europe
ctDNA analysis
The Christie NHS Foundation Trust, Bristol-Myers Squibb, University of Manchester, Manchester Academic Health Science Centre
Melanoma
04/23
05/24
plexifpc, NCT03741101 / 2018-001846-32: Treatment of NF1-related Plexiform Neurofibroma With Trametinib

Active, not recruiting
2
15
Europe
Trametinib, mekinist
Region Skane, Novartis
Neurofibromatosis 1, Child, Neurofibroma, Plexiform
07/24
12/24
NCT02881242: Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Active, not recruiting
2
14
US
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
Jonsson Comprehensive Cancer Center, Stand Up To Cancer, Novartis, Prostate Cancer Foundation
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
01/24
01/25
NCT04417621 / 2020-000873-26: Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Active, not recruiting
2
134
Europe, US, RoW
LXH254, LTT462, Trametinib, Ribociclib
Novartis Pharmaceuticals
Melanoma
08/24
09/24
PaTcH, NCT05518110: Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

Recruiting
2
22
Europe
Trametinib, Hydroxychloroquine
Cancer Trials Ireland, Novartis
Pancreatic Cancer
07/24
04/25
NCT01990196: Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Active, not recruiting
2
45
US
degarelix, Firmagon, FE200486, enzalutamide, Xtandi, MDV3100, trametinib, Mekinist, dasatinib, Sprycel, BMS-354825
Jonsson Comprehensive Cancer Center, Medivation, Inc., GlaxoSmithKline, Prostate Cancer Foundation, Astellas Pharma Inc, Novartis
Prostate Cancer
09/24
09/25
NCT04452877: A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

Active, not recruiting
2
40
RoW
Dabrafenib, DRB436, Trametinib, TMT212
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
11/24
11/24
CA209-8TT, NCT03899155 / 2018-004362-34: Pan Tumor Rollover Study

Recruiting
2
1500
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558-01, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, BMS-986016-01, Nivolumab + Relatlimab, BMS-986213, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
Bristol-Myers Squibb, Exelixis, Novartis, Clovis Oncology, Inc., Janssen Pharmaceuticals
Cancer
08/29
08/29
NEO-ATACT, NCT06079333: NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid ( Study)

Recruiting
2
20
Europe
dabrafenib/trametinib
Leiden University Medical Center, Novartis
Anaplastic Thyroid Cancer
01/27
01/28
MatchMel, NCT02645149: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

Recruiting
2
1000
RoW
Standard therapy or clinical trial, Immunotherapy, Biological agent, Matched targeted therapy, ALK - Ceritinib, BRAF fusion - Trametinib, CCND1 - Ribociclib + Trametinib, CDK4/6 - Ribociclib + Trametinib, CDKN2A - Ribociclib + Trametinib, GNA11 - Trametinib, GNAQ - Trametinib, HRAS - Trametinib, KIT - Pazopanib, KRAS - Trametinib, MAP2K1 - Trametinib, NF1 - Trametinib, MET - Ceritinib, RAS - Ribociclib + Trametinib, ROS1 - Ceritinib, Trametinib and / or supportive care, Trametinib, Supportive care, CDK4/6 and MEK inhibitor, Ribociclib + Trametinib, Compassionate Access Targeted Therapy, Off label use of a matched targeted therapy currently unavailable to the study
Melanoma Institute Australia, Novartis
Melanoma
07/27
12/28
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
Swecranio, NCT05525273: Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma

Recruiting
2
25
Europe
Oral dabrafenib and trametinib
Eva Marie Erfurth, MD, PhD, Novartis
Craniopharyngioma
09/27
04/28
2021-003398-79: International study in which the idea is to use the abnormalities of the bloodtumor of children, that is either not responsive to standard therapy or has returned, as a starting point for a new therapy. Internationale studie waarin het idee is om de afwijkingen van de bloedtumor bij kinderen, die of ongevoelig is voor standaard therapie of die is teruggekomen, te gebruiken als vertrekpunt voor een nieuwe behandeling.

Not yet recruiting
1/2
26
Europe
Trametinib, TMT212, Film-coated tablet, Powder for oral solution, Mekinist
Princess Máxima Center for pediatric oncology, European Science Foundation - Fight Kids Cancer
Molecularly profiled r/r ALL/LBL whose tumor harbors an actionable event that can be targeted by the investigational agents. In this subprotocol, patients must present alterations in the RAS signaling pathway. Moleculaire geprofileerde r/r/ ALL/LBL waarvan de tumor een target heeft voor de onderzoeksmedicatie. In dit sub-protocol moet de tumor een verandering hebben in de RAS signaal transductie route., relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) with activating mutations of the RAS signaling pathway recidief of refractaire acute lymfatische leukemie (ALL) of lymfoblastisch lymfoom(LL) met activerende mutaties van het RAS-signaalpad., Diseases [C] - Cancer [C04]
 
 
2019-001399-13: MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable NRAS Melanoma: A Phase Ib/II Trial of Trametinib plus Hydroxychloroquine in Patients with NRAS Melanoma. CHLORO TRAM MEL Etude de phase I/II évaluant la tolérance d’un traitement par hydroxychloroquine associé au tramétinib dans le mélanome NRAS muté métastatique ou localement avancé non résécable après échec d’une immunothérapie. CHLORO TRAM MEL

Not yet recruiting
1/2
29
Europe
Trametinib, Sulfate d'hydroxychloroquine, Tablet, Mekinist, Plaquenil
Hospices Civils de Lyon, Health ministry, Novartis
Patients with metastatic NRAS melanoma, Patients with metastatic NRAS melanoma, Diseases [C] - Cancer [C04]
 
 
2014-002209-39: Phase I/II study with lapatinib plus trametinib in patients with metastatic non-small cell lung cancer with a mutation in the KRAS gene Fase I/II studie met de combinatie van lapatinib met trametinib bij patiënten met uitgezaaid niet kleincellig longkanker met een KRAS genmutatie

Ongoing
1/2
132
Europe
Lapatinib, trametinib, docetaxel, Tablet, Film-coated tablet, Concentrate and solvent for concentrate for solution for infusion, Mekinist
The Netherlands Cancer Institute, Novartis
non-small cell lung cancer niet-kleincellig longkanker, lung cancer longkanker, Diseases [C] - Cancer [C04]
 
 
SWOG-S1221, NCT01902173: Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Active, not recruiting
1/2
27
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel, Uprosertib, GSK2141795, Oral Akt Inhibitor GSK2141795
National Cancer Institute (NCI), GlaxoSmithKline, Novartis Pharmaceuticals
Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
05/18
10/24
2019-004819-31: First in human study assessing the safety, immunogenicity and efficacy of the cancer vaccine IN01 as second line of treatment in RAS and BRAF mutated metastatic colorectal cancer patients

Not yet recruiting
1/2
70
Europe
trametinib, encorafenib, IN01, Emulsion and suspension for emulsion for injection, Tablet, Capsule, hard, MEKINIST, BRAFTOVI
IN3BIO, IN3BIO
colorectal cancer at a metastatic stage, eligible for a second line treatment and presenting with a constitutive BRAF or RAS mutation, patients with a colorectal cancer with distant metastasis and laboratory identified BRAF or RAS constitutive tumour mutations eligible to receive a second line treatment, Diseases [C] - Cancer [C04]
 
 
2021-006196-42: Study of JDQ443 , in combination with trametinib or ribociclib or cetuximab, in advanced cancer with a specific mutation (changes in a gene) called KRAS G12C

Not yet recruiting
1/2
450
Europe
JDQ443, TMT212, ribociclib, cetuximab, JDQ443, TMT212, LEE011, Tablet, Film-coated tablet, Solution for infusion, Mekinist, Kisqali, Erbitux
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors, advanced cancer with a specific mutation (G12C) in the KRAS gene, Diseases [C] - Cancer [C04]
 
 
2021-005167-51: A trial to determine the safety of CC-92480 when combined with novel compounds in people who have Multiply Myeloma that is not responsive after treatment or has returned after a period of treatment Un ensayo para determinar la seguridad de CC-92480 cuando se combina con compuestos novedosos en personas con mieloma múltiple que no responde después del tratamiento o ha regresado después de un período de tratamiento

Not yet recruiting
1/2
60
Europe
CC-92480, BET-Inhibitor, Tazemetostat (Tazverik), Trametinib Mekinist, Dexamethasone, BMS-986158, TMT212, Capsule, hard, Capsule, Tablet, Tazemetostat (Tazverik), Trametinib Mekinist
Celgene Corporation, Celgene Corporation
Relapsed or Refractory Multiple Myeloma (RRMM) Mieloma múltiple recidivante o resistente (MMRR), Cancer of plasma cells Cancer de células plasmáticas, Diseases [C] - Cancer [C04]
 
 
TRIDENT-2, NCT05071183: A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Hourglass Jan 2023 - Dec 2023 : Data readout from P1b/2 TRIDENT-2 trial in combination with trametinib for KRAS mutant solid tumors
Terminated
1/2
9
US
TPX-0005, repotrectinib, Trametinib, Mekinist
Turning Point Therapeutics, Inc.
KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor
03/23
03/23
NCT04326283: Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
1/2
23
RoW
Trametinib (0.5 mg), Meqsel, SNR1611, Trametinib (1 mg), Riluzole (100 mg), Yooritek
Genuv Inc.
Amyotrophic Lateral Sclerosis
04/23
04/23
CheckMate 9N9, NCT03377361 / 2017-001830-24: An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

Active, not recruiting
1/2
232
Europe, Canada, US, RoW
Nivolumab, Opdivo, BMS-936558, Trametinib, Mekinist, Ipilimumab, Yervoy, BMS-734016, Regorafenib
Bristol-Myers Squibb, Novartis
Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
03/24
03/24
NCT04892017: A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Recruiting
1/2
173
US
DCC-3116, Trametinib, Binimetinib, Sotorasib
Deciphera Pharmaceuticals LLC
Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
08/27
08/28
2015-002615-15: A comparison of the effects of standard melanoma treatment in combination with BGB324, an investigational agent, to standard treatment alone

Not yet recruiting
1/2
92
Europe
BGB324, Capsule, hard, Powder for infusion, Film-coated tablet, Concentrate for solution for infusion, Keytruda, Tafinlar, Mekinist
Helse Bergen HF, Haukeland universitetssjukehus, Kreftforeningen, BerGenBio, KLINBEFORSK
Advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanoma, Melanoma, the most Dangerous form of skin cancer, Diseases [C] - Cancer [C04]
 
 
NCT02872259: BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Checkmark Updated results in combination with dabrafenib/trametinib/pembrolizumab for metastatic melanoma
Oct 2018 - Oct 2018: Updated results in combination with dabrafenib/trametinib/pembrolizumab for metastatic melanoma
Checkmark Presentation of combination study with Tafinlar and BGB324 at ASCO 2018
Jun 2018 - Jun 2018: Presentation of combination study with Tafinlar and BGB324 at ASCO 2018
Completed
1/2
74
Europe
BGB324+pembrolizumab, Keytruda, BGB324+dabrafenib and trametinib, Tafinlar, Mekinist, pembrolizumab, dabrafenib and trametinib
Haukeland University Hospital, BerGenBio ASA
Melanoma
05/24
05/24
NCT06456138: Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Not yet recruiting
1/2
60
RoW
Trametinib, Anlotinib, Tislelizumab
Shanghai Chest Hospital, BeiGene, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis
KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor
06/26
12/28
NCT03455764: MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

Active, not recruiting
1/2
43
US
MCS110, Dabrafenib, Tafinlar, Trametinib, Mekinist
Dana-Farber Cancer Institute, Novartis
Melanoma
09/24
09/25
ENHANCE, NCT05275374: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

Not yet recruiting
1/2
221
NA
XP-102, Trametinib
Xynomic Pharmaceuticals, Inc.
Cancer, BRAF V600 Mutation, Melanoma, Colorectal Cancer, Thyroid Cancer, Nonsmall Cell Lung Cancer
12/25
12/26
NCT05874414: Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma

Recruiting
1/2
74
US
GNS561 + Trametinib, Ezurpimtrostat (GNS561)
Genfit
Cholangiocarcinoma
05/26
10/26
CA057-003, NCT05372354: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
1/2
220
Europe, Canada, US
CC-92480, BMS-986348, Tazemetostat, BMS-986158, Trametinib, Dexamethasone
Bristol-Myers Squibb
Multiple Myeloma
10/26
10/26
NCT05668585: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Recruiting
1/2
206
Europe, US
CFT1946, Trametinib, Cetuximab
C4 Therapeutics, Inc.
Solid Tumors, Melanoma, NSCLC, CRC, ATC
03/27
04/27
KontRASt-03, NCT05358249: Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Recruiting
1/2
346
Europe, US, RoW
JDQ443, trametinib, TMT212, Ribociclib, LEE011, cetuximab
Novartis Pharmaceuticals
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal
05/27
06/27
NCT03088176: Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

Active, not recruiting
1b
4
US
Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Imlygic, Talimogene Laherparep 100 Mil Pfu/Ml 1Ml, Dabrafenib, Tafinlar, Trametinib, Mekinist
West Cancer Center, University of Tennessee Health Science Center, Amgen
Melanoma, BRAF Gene Mutation
11/20
06/21
NCT03272464: INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Terminated
1
1
US
Trametinib, Mekinist, Dabrafenib, Tafinlar, INCB039110, Itacitinib
Massachusetts General Hospital, Incyte Corporation
Melanoma
07/19
12/19
NCT03299088: Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

Active, not recruiting
1
15
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of California, Davis, Merck Sharp & Dohme LLC, Novartis, National Cancer Institute (NCI)
KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
01/21
06/24
NCT01740648: Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer

Completed
1
19
US
trametinib, GSK1120212, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, radiation therapy, irradiation, radiotherapy, therapy, radiation
Ohio State University Comprehensive Cancer Center, National Comprehensive Cancer Network, Novartis Pharmaceuticals
Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
09/21
09/21
NCT03091257: A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Recruiting
1
30
US
Dabrafenib, Tafinlar, Trametinib, Mekinist
Massachusetts General Hospital, Novartis, Multiple Myeloma Research Consortium, Barbara Ann Karmanos Cancer Institute
Multiple Myeloma
09/24
09/24
SJDAWN, NCT03434262: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Completed
1
68
US
Gemcitabine, Gemzar®, ribociclib, LEE011, LEE-011, KISQALI®, sonidegib, LDE225, LDE-225, ODOMZO®, trametinib, TMT212, TMT-212, MEKINIST(TM), filgrastim, G-CSF
St. Jude Children's Research Hospital, Novartis Pharmaceuticals
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
09/22
05/24
TRAHD, NCT03714958: Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type

Completed
1
12
Europe
HDM201, Trametinib
Centre Leon Berard, Novartis
Colorectal Cancer, Advanced Cancer, Metastatic Cancer
09/23
09/23
NCT03501368: Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Active, not recruiting
1
27
US
Ceritinib, ZYKADIA, Trametinib, MEKINIST
H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals
Melanoma, Unresectable Melanoma, Advanced Melanoma
10/22
08/24
THREAD, NCT03825289: Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

Recruiting
1
39
US
Hydroxychloroquine, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of Utah, Novartis Pharmaceuticals
Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Pancreatic Carcinoma
01/25
01/26
NCT04111458: A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

Active, not recruiting
1
71
Europe, US
BI 1701963, Trametinib
Boehringer Ingelheim
Solid Tumors, KRAS Mutation; SOS1
10/24
10/24
NCT02974725: A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Terminated
1
241
Europe, US, RoW
LXH254, LTT462, Trametinib, Ribociclib
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Melanoma
04/24
04/24
NCT04294160: A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Active, not recruiting
1
122
Europe, Canada, US, RoW
Dabrafenib, DRB436, Tafinlar, LTT462, Trametinib, TMT212, Mekinist, LXH254, TNO155, Spartalizumab, PDR001, Tislelizumab, VDT482, BGBA317
Novartis Pharmaceuticals
BRAF V600 Colorectal Cancer
10/24
10/24
NCT04965220: HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors

Recruiting
1
220
RoW
HLX 208, trametinib
Shanghai Henlius Biotech
Solid Tumor
06/24
06/25
NCT03085056: Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Active, not recruiting
1
13
US
Trametinib, Paclitaxel
Memorial Sloan Kettering Cancer Center, Novartis
Anaplastic Thyroid Cancer
09/25
09/25
NCT03333343: Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Active, not recruiting
1
105
Europe, Canada, RoW
EGF816, trametinib, ribociclib, LXH254, INC280, gefitinib
Novartis Pharmaceuticals
EGFR-mutant Non-small Cell Lung Cancer
12/24
12/24
NCT05048134: A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Recruiting
1
345
RoW
HRS2300, HRS2300、 SHR-1316, HRS2300、SHR-1701, HRS2300、trametinib, HRS2300、Almonertinib
Jiangsu HengRui Medicine Co., Ltd.
Advanced Malignancies
01/25
03/25
NCT05440942: Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
1
35
US
Trametinib, GSK1120212, TMT212-NXA, Mekinist, Ruxolitinib, INCB018424, INC424, Retifanlimab, INCMGA00012
Peter Hosein, MD, Incyte Corporation, Novartis Pharmaceuticals, University of Miami Sylvester Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma
03/25
09/27
SEACRAFT-1, NCT05907304: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Recruiting
1
115
Europe, Canada, US, RoW
Naporafenib, LXH254, ERAS-254, Trametinib, Mekinist
Erasca, Inc.
Advanced or Metastatic Solid Tumors
07/25
11/25
CodeBreak101, NCT04185883: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Checkmark Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
More
Recruiting
1
1200
Europe, Canada, Japan, US, RoW
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Amgen
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
12/26
12/27
NCT05435846: Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Terminated
1
3
US
Capmatinib, INC280, Trametinib, TMT212, Mekinist
Collin Blakely, Novartis
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer
11/23
05/24
NCT04903119: Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Recruiting
1
15
US
Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg, Nilotinib 400mg, Dabrafenib, Trametinib
Ruta Arays, Novartis, National Cancer Institute (NCI)
Metastatic Melanoma, BRAF Gene Mutation
12/26
03/27
NCT04485559: Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Recruiting
1
50
US
Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of California, San Francisco, Novartis Pharmaceuticals, Pediatric Brain Tumor Foundation, The Lilabean Foundation for Pediatric Brain Cancer Research
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma
12/27
12/27
NCT02416232 / 2014-005149-40: Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

No Longer Available
N/A
Europe
Trametinib, Dabrafenib
GlaxoSmithKline
Melanoma
 
 
NCT03386071: Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

No Longer Available
N/A
NA
Trametinib 2 mg
Jonsson Comprehensive Cancer Center, Novartis
Progressive Metastatic Castrate Resistant Prostate Cancer
 
 
NCT05806268: Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients

Completed
N/A
214
US
Novartis Pharmaceuticals
BRAF v600 Mutated Metastatic Melanoma
03/22
03/22
NCT05848219: Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib

Terminated
N/A
543
US
Novartis Pharmaceuticals
Metastatic Melanoma
04/22
04/22
NCT06337617: A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

Completed
N/A
90
RoW
Novartis Pharmaceuticals
BRAF V600 Mutation Positive Melanoma
06/23
06/23
NCT04547946: Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

Completed
N/A
3
Europe
dabrafenib + trametinib
Novartis Pharmaceuticals
Malignant Melanoma
06/22
06/22
NCT04507919: Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Available
N/A
NA
Dabrafenib, twice daily (BID), Trametininb, once daily (QD)
Novartis Pharmaceuticals
Small Cell Lung Carcinoma
 
 
RATIONALE, NCT05171374: pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE

Recruiting
N/A
500
RoW
Dabrafenib, Trametinib
MelanomaPRO, Russia, Novartis
Melanoma Stage III, Melanoma Stage IV, Melanoma
09/23
09/24
NCT04489433: Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Available
N/A
NA
Dabrafenib and Trametinib, Dabrafenib, Trametinib
Novartis Pharmaceuticals
Melanoma
 
 
NCT04544202: Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Available
N/A
NA
Dabrafenib and Trametinib, Dabrafenib, Trametinib
Novartis Pharmaceuticals
Melanoma, Adjuvant
 
 
LEAD Melanoma, NCT04961619: Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.

Recruiting
N/A
84
RoW
dabrafenib, trametinib
Novartis Pharmaceuticals
Melanoma
12/24
12/24
Combi-EU, NCT03944356: BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

Active, not recruiting
N/A
232
Europe
Dabrafenib and Trametinib, Tafinlar and Mekinist
EuMelaReg gGmbH
Melanoma
12/23
06/24
NCT06262919: Special Drug Use-results Surveillance of Tafinlar/Mekinist

Recruiting
N/A
90
Japan
Tafinlar/Mekinist, Dabrafenib/trametinib
Novartis Pharmaceuticals
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
12/31
12/31
OCEANMIST, NCT05260684: Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

Completed
N/A
1
US
Encorafenib, Administration route: Oral, Binimetinib, Vemurafenib, Cobimetinib, Dabrafenib, Trametinib
Pfizer
Melanoma
12/23
12/23
NCT04666272: Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Recruiting
N/A
80
RoW
dabrafenib, trametinib
Novartis Pharmaceuticals
Melanoma
07/29
07/29
NCT05868629: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Recruiting
N/A
40
US
Non-investigational
Novartis Pharmaceuticals
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
02/28
02/28
CA209-7PG, NCT05432622: A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

Completed
N/A
95
US
Bristol-Myers Squibb
Melanoma
04/23
07/23

Download Options